Somatostatin-dopamine chimeric molecules in neuroendocrine neoplasms

Maria Celeste Cantone, Alessandra Dicitore, Giovanni Vitale

Research output: Contribution to journalReview articlepeer-review


Neuroendocrine neoplasms (NENs) are a widely heterogeneous family of neoplasms arising from neuroendocrine cells, which are interspersed throughout the body. Despite NENs are relatively rare, their incidence and prevalence are constantly increasing probably due to the improvement in earlier diagnosis and patients’ management. When surgery is not curative, particularly for patients with metastatic disease, several medical options are available. Somatostatin analogues (SSA) are the first-line medical therapy for well-differentiated NENs. Interestingly, the heterodimerization of somatostatin receptors (SSTs) with dopamine receptors (DRs) has been discovered in NENs. This phenomenon results in hybrid receptors with enhanced functional activity. On these bases, chimeric molecules embracing somatostatin and dopamine features have been recently developed. The aim of this review is to provide a comprehensive overview of the available preclinical and clinical data regarding chimeric somatostatin-dopamine agonists as a new class of “magic bullet” in the therapy of NENs.

Original languageEnglish
Article number501
Pages (from-to)1-18
Number of pages18
JournalJournal of Clinical Medicine
Issue number3
Publication statusPublished - 2021


  • Dopamine receptors
  • Neuroendocrine neoplasms
  • Somatostatin receptors
  • Somatostatin-dopamine chimeric compounds

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Somatostatin-dopamine chimeric molecules in neuroendocrine neoplasms'. Together they form a unique fingerprint.

Cite this